Prosthetic Valve Thrombosis: About 205 Patients

Abstract

Background: The prosthetic heart valve thrombosis (PVT) is a life-threatening complication of mechanical valve prosthesis. It can be attributed more frequently to inadequate anticoagulant therapy. In the aortic and mitral position, reported incidences vary widely from 0.5% to 6% per patient-year, and are highest in the mitral position and up to 20% in tricuspid valve prosthesis. Medical therapy (Thrombolysis) has emerged as an alternative therapy in high-risk surgical patients, considering that surgical prosthetic valve replacement is related to significant operative morbidity and mortality rates. The purpose of this study is to present a single-center experience of 205 consecutive patients hospitalized between 2000 and 2016.

Prosthetic valve thrombosis – association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes

“…Prosthetic Valve Thrombosis (PVT) is a rare but serious complication of mechanical heart valve and is associated with significant mortality and morbidity. [1] PVT is an obstruction of a prosthetic valve by non infective thrombotic material. The occurrence of PVT depends on the thrombogenicity of the prosthetic valve, hemodynamic of the transprosthetic blood flow and ineffective anticoagulation.…”